Imfinzi granted priority review and breakthrough therapy designation for patients with limited-stage small cell lung cancer in the US

AstraZeneca

15 August 2024 - Based on ADRIATIC Phase 3 trial which demonstrated statistically significant and clinically meaningful overall survival and progression-free survival benefit.

AstraZeneca’s supplemental biologics license application for Imfinzi (durvalumab), based on the results from the positive ADRIATIC Phase 3 trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy, has been accepted and granted priority review in the US.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder